  Imaging of microvasculature is primarily performed with X-ray contrast
agents, owing to the wide availability of absorption-contrast laboratory source
microCT compared to phase contrast capable devices. Standard commercial
contrast agents used in angiography are not suitable for high-resolution
imaging ex vivo, however, as they are small molecular compounds capable of
diffusing through blood vessel walls within minutes. Large nanoparticle-based
blood pool contrast agents on the other hand exhibit problems with aggregation,
resulting in clogging in the smallest blood vessels. Injection with solidifying
plastic resins has, therefore, remained the gold standard for microvascular
imaging, despite the considerable amount of training and optimization needed to
properly perfuse the viscous compounds. Even with optimization, frequent gas
and water inclusions commonly result in interrupted vessel segments. This lack
of suitable compounds has led us to develop the polymeric, cross-linkable X-ray
contrast agent XlinCA. As a water-soluble organic molecule, aggregation and
inclusions are inherently avoided. High molecular weight allows it to be
retained even in the highly fenestrated vasculature of the kidney filtration
system. It can be covalently crosslinked using the same aldehydes used in
tissue fixation protocols, leading to stable and permanent contrast. These
properties allowed us to image whole mice and individual organs in 6 to
12-month-old C57BL/6J mice without requiring lengthy optimizations of injection
rates and pressures, while at the same time achieving greatly improved filling
of the vasculature compared to resin-based vascular casting. This work aims at
illuminating the rationales, processes and challenges involved in creating this
recently developed contrast agent.
